Ketamine Infusion for Treatment-resistant Major Depressive Disorder
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Ketamine infusion has been shown to have rapid antidepressant properties, however the
possible use of ketamine in treatment-resistant depression as augmentation has not been
investigated. The overall aim of this study is to assess the feasibility, safety and
tolerability, efficacy and duration of the effect of intravenous N-methyl-D-aspartate
antagonist ketamine as augmentation of antidepressants for chronic suicidal ideation in
subjects with severe treatment-resistant depression (TRD).
This is an open-label study (pilot).